feat(asl): Implement full-text screening core LLM service and validation system (Day 1-3)
Core Components: - PDFStorageService with Dify/OSS adapters - LLM12FieldsService with Nougat-first + dual-model + 3-layer JSON parsing - PromptBuilder for dynamic prompt assembly - MedicalLogicValidator with 5 rules + fault tolerance - EvidenceChainValidator for citation integrity - ConflictDetectionService for dual-model comparison Prompt Engineering: - System Prompt (6601 chars, Section-Aware strategy) - User Prompt template (PICOS context injection) - JSON Schema (12 fields constraints) - Cochrane standards (not loaded in MVP) Key Innovations: - 3-layer JSON parsing (JSON.parse + json-repair + code block extraction) - Promise.allSettled for dual-model fault tolerance - safeGetFieldValue for robust field extraction - Mixed CN/EN token calculation Integration Tests: - integration-test.ts (full test) - quick-test.ts (quick test) - cached-result-test.ts (fault tolerance test) Documentation Updates: - Development record (Day 2-3 summary) - Quality assurance strategy (full-text screening) - Development plan (progress update) - Module status (v1.1 update) - Technical debt (10 new items) Test Results: - JSON parsing success rate: 100% - Medical logic validation: 5/5 passed - Dual-model parallel processing: OK - Cost per PDF: CNY 0.10 Files: 238 changed, 14383 insertions(+), 32 deletions(-) Docs: docs/03-涓氬姟妯″潡/ASL-AI鏅鸿兘鏂囩尞/05-寮€鍙戣褰?2025-11-22_Day2-Day3_LLM鏈嶅姟涓庨獙璇佺郴缁熷紑鍙?md
This commit is contained in:
589
backend/test-output/quick-test-result.json
Normal file
589
backend/test-output/quick-test-result.json
Normal file
@@ -0,0 +1,589 @@
|
||||
{
|
||||
"pdf": "rayyan-256859669.pdf",
|
||||
"duration": 133,
|
||||
"totalCost": 0.091123,
|
||||
"degradedMode": false,
|
||||
"modelA": {
|
||||
"model": "deepseek-v3",
|
||||
"cost": 0.019511,
|
||||
"tokenUsage": 19511,
|
||||
"extractionMethod": "pymupdf",
|
||||
"logicValid": true,
|
||||
"evidenceComplete": true,
|
||||
"result": {
|
||||
"fields": {
|
||||
"文献来源": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. Junya Aoki, MD, et al. Journal of Stroke and Cerebrovascular Diseases, Vol. 30, No. 2 (February), 2021: 105494. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105494. Received September 21, 2020; revision received November 15, 2020; accepted November 20, 2020.",
|
||||
"location": {
|
||||
"section": "Title page",
|
||||
"subsection": "Header and footer",
|
||||
"paragraph": 1,
|
||||
"page": 1
|
||||
},
|
||||
"keywords": [
|
||||
"Journal of Stroke and Cerebrovascular Diseases",
|
||||
"105494",
|
||||
"2021"
|
||||
]
|
||||
},
|
||||
"reasoning": "论文提供了完整的文献来源信息：第一作者、年份、期刊名称、卷期号、页码和DOI号，符合完整标准",
|
||||
"confidence": 0.99,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"研究类型": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "This post-hoc study extracted the patient data from the ADS registry, a multicenter, prospective, randomized, open-label trial that evaluated the safety and efficacy of acute aspirin plus cilostazol dual therapy in patients with non-cardioembolic stroke within 48 h of symptom onset. The ADS trial was performed between May 2011 and June 2017 and involved 34 centers in Japan. Patients were randomly allocated to either the DAPT group or the aspirin group.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 1,
|
||||
"page": 2
|
||||
},
|
||||
"keywords": [
|
||||
"randomized",
|
||||
"open-label trial",
|
||||
"multicenter",
|
||||
"prospective"
|
||||
]
|
||||
},
|
||||
"reasoning": "明确说明为随机、开放标签、多中心临床试验的事后分析，研究类型描述清晰完整",
|
||||
"confidence": 0.98,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"研究设计细节": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "The ADS trial was performed between May 2011 and June 2017 and involved 34 centers in Japan. Patients were randomly allocated to either the DAPT group or the aspirin group. The DAPT group was treated with cilostazol (200 mg/day) and aspirin (80-200 mg/day) for 14 days, while the aspirin group was treated with only aspirin (80-200 mg/day) for 14 days. Concomitant anticoagulant therapy with heparin and argatroban was permitted since it was widely used in clinical practice in Japan during the study period.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 1,
|
||||
"page": 2
|
||||
},
|
||||
"keywords": [
|
||||
"34 centers",
|
||||
"14 days",
|
||||
"May 2011 and June 2017",
|
||||
"follow-up period"
|
||||
]
|
||||
},
|
||||
"reasoning": "提供了完整的研究设计细节：研究时间范围、中心数量、随访时间、治疗持续时间，符合完整标准",
|
||||
"confidence": 0.95,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"疾病诊断标准": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Stroke etiologies were re-classified based on the TOAST criteria by a certified vascular neurologist (J.A), and only patients who were diagnosed with ischemic stroke due to LAA, SVO, Others, or Undetermined etiologies were analyzed. According to the TOAST criteria, ischemic stroke is divided into five subgroups: large artery atherosclerosis (LAA), small vessel occlusion (SVO), cardioembolic stroke (CES), other determined etiology (Others), and undetermined etiology (Undetermined).",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Inclusion and exclusion criteria",
|
||||
"paragraph": 2,
|
||||
"page": 3
|
||||
},
|
||||
"keywords": [
|
||||
"TOAST criteria",
|
||||
"certified vascular neurologist",
|
||||
"LAA",
|
||||
"SVO",
|
||||
"Others",
|
||||
"Undetermined"
|
||||
]
|
||||
},
|
||||
"reasoning": "明确使用TOAST分类标准，由认证血管神经科医生重新分类，诊断标准清晰完整",
|
||||
"confidence": 0.96,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"人群特征": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Between February 2011 and March 2017, 1208 patients were enrolled in the ADS trial. Seven patients withdrew their consent after the study started, 10 patients were lost to follow-up at 14 days, and 125 patients discontinued the allocated therapy. Of the remaining 1066 patients, 1022 (686 [67%] men; median age [interquartile range], 69 [60-77] years old; initial NIHSS score, 2 [1-4]) with non-cardioembolic stroke were analyzed. In total, 164 (16%), 630 (62%), 70 (7%), and 158 (15%) patients were diagnosed with ischemic stroke due to LAA, SVO, Other, and Undetermined etiologies, respectively.",
|
||||
"location": {
|
||||
"section": "Results",
|
||||
"subsection": "Patient enrollment",
|
||||
"paragraph": 1,
|
||||
"page": 3
|
||||
},
|
||||
"keywords": [
|
||||
"1022 patients",
|
||||
"67% men",
|
||||
"median age 69",
|
||||
"NIHSS score 2",
|
||||
"stroke subtypes"
|
||||
]
|
||||
},
|
||||
"reasoning": "提供了完整的人群特征：总样本量、性别分布、年龄范围、基线NIHSS评分、各亚型分布，信息充分完整",
|
||||
"confidence": 0.97,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"基线数据": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Table 1 shows the clinical backgrounds based on the stroke subtypes. Patients in the SVO group and those in the LAA group were younger and older, respectively, than those in other groups (p = 0.001). Dyslipidemia was less frequent in the Undetermined group than in others (p = 0.047). Systolic and diastolic blood pressures were the highest in the SVO group (p = 0.003 and p = 0.001, respectively). The proportion of aspirin therapy before stroke was the highest in the LAA group (p = 0.032).",
|
||||
"location": {
|
||||
"section": "Results",
|
||||
"subsection": "Subtype analysis",
|
||||
"paragraph": 1,
|
||||
"page": 3
|
||||
},
|
||||
"keywords": [
|
||||
"Table 1",
|
||||
"clinical backgrounds",
|
||||
"blood pressure",
|
||||
"dyslipidemia",
|
||||
"aspirin therapy"
|
||||
]
|
||||
},
|
||||
"reasoning": "通过Table 1提供了详细的基线数据，包括人口统计学特征、合并症、血压、实验室检查等，基线数据完整",
|
||||
"confidence": 0.95,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"干预措施": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "The DAPT group was treated with cilostazol (200 mg/day) and aspirin (80-200 mg/day) for 14 days, while the aspirin group was treated with only aspirin (80-200 mg/day) for 14 days. Concomitant anticoagulant therapy with heparin and argatroban was permitted since it was widely used in clinical practice in Japan during the study period.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 1,
|
||||
"page": 2
|
||||
},
|
||||
"keywords": [
|
||||
"cilostazol 200 mg/day",
|
||||
"aspirin 80-200 mg/day",
|
||||
"14 days",
|
||||
"concomitant anticoagulant"
|
||||
]
|
||||
},
|
||||
"reasoning": "明确描述了干预措施的具体药物、剂量、疗程，以及允许的合并用药，干预措施描述完整",
|
||||
"confidence": 0.96,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"对照措施": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Patients were randomly allocated to either the DAPT group or the aspirin group. The DAPT group was treated with cilostazol (200 mg/day) and aspirin (80-200 mg/day) for 14 days, while the aspirin group was treated with only aspirin (80-200 mg/day) for 14 days.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 1,
|
||||
"page": 2
|
||||
},
|
||||
"keywords": [
|
||||
"aspirin group",
|
||||
"aspirin 80-200 mg/day",
|
||||
"14 days",
|
||||
"monotherapy"
|
||||
]
|
||||
},
|
||||
"reasoning": "明确描述了对照组使用阿司匹林单药治疗，剂量和疗程与干预组一致，对照措施描述完整",
|
||||
"confidence": 0.95,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"结局指标": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "In the ADS, the following primary outcomes were evaluated: neurological worsening, transient ischemic attack (TIA), and stroke recurrence within 14 days. Neurological deterioration included neurological progression with an NIHSS score of ≥2 and recurrent ischemic stroke or TIA within 14 days, as defined in the ADS. Fourteen days after stroke onset, 104 (10%) of the 1022 patients showed neurological deterioration—53 (11%) patients in the DAPT group and in 51 (10%) patients in the aspirin group (p = 0.469).",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry and Study purpose",
|
||||
"paragraph": 2,
|
||||
"page": 2
|
||||
},
|
||||
"keywords": [
|
||||
"neurological worsening",
|
||||
"TIA",
|
||||
"stroke recurrence",
|
||||
"NIHSS score ≥2",
|
||||
"14 days"
|
||||
]
|
||||
},
|
||||
"reasoning": "明确定义了主要结局指标（神经功能恶化、TIA、卒中复发）及其具体标准（NIHSS评分增加≥2），结果报告完整",
|
||||
"confidence": 0.97,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"统计方法": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "The Mann-Whitney U test was used to analyze differences in continuous variables, and Fisher's exact test and Pearson chi-square were used to analyze differences in categorical variables. The data are presented as median values (interquartile range [IQR]) or frequencies (%). Variables identified on univariate analyses with p values <0.1 as well as the age and gender were entered into the multivariate analysis. The relative risks of complete recanalization at 24 h were expressed as odds ratios (OR) with 95% confidence intervals (CIs). All statistical analyses were performed using the SPSS software program, version 22.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Statistical analyses",
|
||||
"paragraph": 1,
|
||||
"page": 3
|
||||
},
|
||||
"keywords": [
|
||||
"Mann-Whitney U test",
|
||||
"Fisher's exact test",
|
||||
"multivariate analysis",
|
||||
"odds ratios",
|
||||
"SPSS"
|
||||
]
|
||||
},
|
||||
"reasoning": "详细描述了统计分析方法：连续变量和分类变量的检验方法、多变量分析入选标准、结果表达方式、软件版本，统计方法完整",
|
||||
"confidence": 0.96,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
},
|
||||
"质量评价": {
|
||||
"assessment": "不完整",
|
||||
"evidence": {
|
||||
"quote": "This post-hoc study extracted the patient data from the ADS registry, a multicenter, prospective, randomized, open-label trial. Patients were randomly allocated to either the DAPT group or the aspirin group. In this post-hoc analysis, only patients with ischemic stroke patients who had successfully continued the allocated therapy and received the 14-day assessment were included. Therefore, patients who were unable to continue the therapy for reasons including side effects and allergic reactions and those who did not receive the 14-day assessment were excluded.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry and Inclusion criteria",
|
||||
"paragraph": 1,
|
||||
"page": "2-3"
|
||||
},
|
||||
"keywords": [
|
||||
"randomized",
|
||||
"open-label",
|
||||
"excluded patients",
|
||||
"per-protocol analysis"
|
||||
]
|
||||
},
|
||||
"reasoning": "研究为开放标签设计，未描述盲法实施；随机化方法未具体说明（如序列生成、分配隐藏）；采用符合方案集分析而非ITT分析；失访处理描述不充分",
|
||||
"confidence": 0.85,
|
||||
"cochrane_assessment": "High risk",
|
||||
"cochrane_details": {
|
||||
"domains": {
|
||||
"随机化过程": {
|
||||
"risk": "Unclear risk",
|
||||
"reasoning": "仅提到'随机分配'，未描述随机序列生成方法和分配隐藏措施"
|
||||
},
|
||||
"偏离预期干预": {
|
||||
"risk": "High risk",
|
||||
"reasoning": "开放标签设计，未实施盲法，可能影响干预实施和结局评估"
|
||||
},
|
||||
"结局数据缺失": {
|
||||
"risk": "Some concerns",
|
||||
"reasoning": "排除未能完成治疗和14天评估的患者（125人），可能引入偏倚"
|
||||
},
|
||||
"结局测量": {
|
||||
"risk": "High risk",
|
||||
"reasoning": "神经功能恶化评估可能受开放标签设计影响"
|
||||
},
|
||||
"选择性报告结果": {
|
||||
"risk": "Low risk",
|
||||
"reasoning": "报告了所有预设结局指标，未见选择性报告"
|
||||
}
|
||||
},
|
||||
"overall_bias_risk": "High risk"
|
||||
}
|
||||
},
|
||||
"其他信息": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Sources of Funding: None. Declaration of Competing Interest: The authors have no conflicts of interest or funding sources to disclose. Acknowledgments: None. This study was approved by the institutional review board of our institutions.",
|
||||
"location": {
|
||||
"section": "End of article",
|
||||
"subsection": "Funding and conflicts",
|
||||
"paragraph": 1,
|
||||
"page": 9
|
||||
},
|
||||
"keywords": [
|
||||
"no funding",
|
||||
"no conflicts of interest",
|
||||
"institutional review board approved"
|
||||
]
|
||||
},
|
||||
"reasoning": "明确声明无资金来源、无利益冲突、获得伦理委员会批准，其他信息完整",
|
||||
"confidence": 0.98,
|
||||
"cochrane_assessment": "Not applicable"
|
||||
}
|
||||
},
|
||||
"processing_log": {
|
||||
"sections_reviewed": [
|
||||
"Abstract",
|
||||
"Introduction",
|
||||
"Methods",
|
||||
"Results",
|
||||
"Discussion",
|
||||
"Tables",
|
||||
"Figures",
|
||||
"References"
|
||||
],
|
||||
"paragraphs_read_per_section": {
|
||||
"Methods": 5,
|
||||
"Results": 8
|
||||
},
|
||||
"middle_sections_attention": true,
|
||||
"total_processing_time_estimate": "18 minutes"
|
||||
},
|
||||
"verification": {
|
||||
"keywords_searched": [
|
||||
"randomization",
|
||||
"blinding",
|
||||
"ITT",
|
||||
"baseline",
|
||||
"dropout",
|
||||
"allocation",
|
||||
"sequence",
|
||||
"intention-to-treat",
|
||||
"lost to follow-up"
|
||||
],
|
||||
"reread_count": 2,
|
||||
"found_missed_info": true,
|
||||
"cross_section_conflicts": [
|
||||
{
|
||||
"conflict": "Methods提到随机分配，但未描述具体随机化方法",
|
||||
"locations": [
|
||||
"Methods section paragraph 1",
|
||||
"No additional details found"
|
||||
]
|
||||
}
|
||||
]
|
||||
},
|
||||
"metadata": {
|
||||
"model_name": "deepseek-v3",
|
||||
"processing_date": "2025-11-22T14:02:55.336Z",
|
||||
"document_format": "plaintext",
|
||||
"estimated_word_count": 27758
|
||||
}
|
||||
}
|
||||
},
|
||||
"modelB": {
|
||||
"model": "qwen-max",
|
||||
"cost": 0.071612,
|
||||
"tokenUsage": 17903,
|
||||
"extractionMethod": "pymupdf",
|
||||
"logicValid": true,
|
||||
"evidenceComplete": true,
|
||||
"result": {
|
||||
"fields": {
|
||||
"文献来源": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Junya Aoki, MD, Yasuyuki Iguchi, MD, Takao Urabe, MD, et al. Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. Journal of Stroke and Cerebrovascular Diseases, Vol. 30, No. 2 (February), 2021: 105494. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105494",
|
||||
"location": {
|
||||
"section": "Abstract",
|
||||
"paragraph": 1
|
||||
}
|
||||
},
|
||||
"reasoning": "提供了第一作者、年份、期刊和DOI，信息完整。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"研究类型": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "This post-hoc study extracted the patient data from the ADS registry, a multicenter, prospective, randomized, open-label trial that evaluated the safety and efficacy of acute aspirin plus cilostazol dual therapy in patients with non-cardioembolic stroke within 48 h of symptom onset.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 1
|
||||
}
|
||||
},
|
||||
"reasoning": "明确指出这是一项多中心、前瞻性、随机、开放标签的试验。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"研究设计细节": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "The ADS trial was performed between May 2011 and June 2017 and involved 34 centers in Japan. Patients were randomly allocated to either the DAPT group or the aspirin group. The DAPT group was treated with cilostazol (200 mg/day) and aspirin (80-200 mg/day) for 14 days, while the aspirin group was treated with only aspirin (80-200 mg/day) for 14 days. Concomitant anticoagulant therapy with heparin and argatroban was permitted since it was widely used in clinical practice in Japan during the study period.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 2
|
||||
}
|
||||
},
|
||||
"reasoning": "详细描述了研究的时间范围、参与中心数量、随访时间（14天）以及数据来源。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"疾病诊断标准": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Stroke subtypes included large-artery athero-sclerosis (LAA), small vessel occlusion (SVO), other determined etiology (Others), and undetermined etiology of stroke (Undetermined).",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Study purpose",
|
||||
"paragraph": 1
|
||||
}
|
||||
},
|
||||
"reasoning": "使用TOAST分类标准对卒中亚型进行了详细的定义。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"人群特征": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Between February 2011 and March 2017, 1208 patients were enrolled in the ADS trial. Seven patients withdrew their consent after the study started, 10 patients were lost to follow-up at 14 days, and 125 patients discontinued the allocated therapy. Of the remaining 1066 patients, 1022 (686 [67%] men; median age [interquartile range], 69 [60-77] years old; initial NIHSS score, 2 [1-4]) with non-cardioembolic stroke were analyzed.",
|
||||
"location": {
|
||||
"section": "Results",
|
||||
"paragraph": 1
|
||||
}
|
||||
},
|
||||
"reasoning": "提供了样本量、性别比例、年龄分布和初始NIHSS评分等详细的人口统计学信息。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"基线数据": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "Table 1 shows the clinical backgrounds based on the stroke subtypes. In total, 164 (16%), 630 (62%), 70 (7%), and 158 (15%) patients were diagnosed with ischemic stroke due to LAA, SVO, Other, and Undetermined etiologies, respectively. Patients in the SVO group and those in the LAA group were younger and older, respectively, than those in other groups (p = 0.001). Dyslipidemia was less frequent in the Undetermined group than in others (p = 0.047). Systolic and diastolic blood pressures were the highest in the SVO group (p = 0.003 and p = 0.001, respectively). The proportion of aspirin therapy before stroke was the highest in the LAA group (p = 0.032).",
|
||||
"location": {
|
||||
"section": "Results",
|
||||
"paragraph": 2
|
||||
}
|
||||
},
|
||||
"reasoning": "提供了不同卒中亚型的基线数据，包括年龄、性别、高血压、糖尿病、血脂异常等。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"干预措施": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "The DAPT group was treated with cilostazol (200 mg/day) and aspirin (80-200 mg/day) for 14 days, while the aspirin group was treated with only aspirin (80-200 mg/day) for 14 days.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 2
|
||||
}
|
||||
},
|
||||
"reasoning": "详细描述了DAPT组和阿司匹林组的药物剂量和疗程。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"对照措施": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "The aspirin group was treated with only aspirin (80-200 mg/day) for 14 days.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 2
|
||||
}
|
||||
},
|
||||
"reasoning": "明确描述了对照组的治疗方案。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"结局指标": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "In the ADS, the following primary outcomes were evaluated: neurological worsening, transient ischemic attack (TIA), and stroke recurrence within 14 days. Neurological deterioration included neurological progression with an NIHSS score of ≥2 and recurrent ischemic stroke or TIA within 14 days, as defined in the ADS.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 3
|
||||
}
|
||||
},
|
||||
"reasoning": "详细描述了主要结局指标，包括神经功能恶化、短暂性脑缺血发作和卒中复发。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"统计方法": {
|
||||
"assessment": "完整",
|
||||
"evidence": {
|
||||
"quote": "First, the clinical characteristics and imaging findings were compared among the stroke subtypes. The impact of DAPT on the neurological deterioration was then compared among the four stroke subtypes. Next, data on each stroke subtype were divided into deterioration and no-deterioration groups based on the presence of neurological deterioration. The clinical characteristics and image findings were then compared between these two groups for each subtype. Finally, a multivariate regression analysis was conducted to evaluate the independent parameters related to neurological deterioration in each TOAST subtype. The Mann-Whitney U test was used to analyze differences in continuous variables, and Fisher's exact test and Pearson chi-square were used to analyze differences in categorical variables. The data are presented as median values (interquartile range [IQR]) or frequencies (%). Variables identified on univariate analyses with p values <0.1 as well as the age and gender were entered into the multivariate analysis. The relative risks of complete recanalization at 24 h were expressed as odds ratios (OR) with 95% confidence intervals (CIs). All statistical analyses were performed using the SPSS software program, version 22 (SPSS Japan, Inc., Tokyo, Japan). Results were considered statistically significant at p<0.05.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Statistical analyses",
|
||||
"paragraph": 1
|
||||
}
|
||||
},
|
||||
"reasoning": "详细描述了统计分析方法，包括单变量和多变量回归分析、Mann-Whitney U检验、Fisher精确检验和Pearson卡方检验。",
|
||||
"confidence": 0.95
|
||||
},
|
||||
"质量评价": {
|
||||
"assessment": "不完整",
|
||||
"evidence": {
|
||||
"quote": "Patients were randomly allocated to either the DAPT group or the aspirin group. The DAPT group was treated with cilostazol (200 mg/day) and aspirin (80-200 mg/day) for 14 days, while the aspirin group was treated with only aspirin (80-200 mg/day) for 14 days. Concomitant anticoagulant therapy with heparin and argatroban was permitted since it was widely used in clinical practice in Japan during the study period.",
|
||||
"location": {
|
||||
"section": "Methods",
|
||||
"subsection": "Patient registry",
|
||||
"paragraph": 2
|
||||
}
|
||||
},
|
||||
"reasoning": "虽然提到了随机分配，但没有具体说明序列生成方法和分配隐藏。盲法也没有详细描述。结果完整性方面，提到失访情况但未提供具体失访率。",
|
||||
"confidence": 0.7,
|
||||
"cochrane_details": {
|
||||
"domains": {
|
||||
"随机化过程": {
|
||||
"risk": "Unclear risk",
|
||||
"reasoning": "仅提到随机分配，无具体序列生成方法和分配隐藏"
|
||||
},
|
||||
"偏离预期干预": {
|
||||
"risk": "Low risk",
|
||||
"reasoning": "详细描述了干预措施和对照措施"
|
||||
},
|
||||
"结局数据缺失": {
|
||||
"risk": "Unclear risk",
|
||||
"reasoning": "提到失访情况但未提供具体失访率"
|
||||
},
|
||||
"结局测量": {
|
||||
"risk": "Low risk",
|
||||
"reasoning": "详细描述了结局指标和测量方法"
|
||||
},
|
||||
"选择性报告结果": {
|
||||
"risk": "Unclear risk",
|
||||
"reasoning": "未提及注册号或预设方案"
|
||||
}
|
||||
},
|
||||
"overall_bias_risk": "Unclear"
|
||||
}
|
||||
},
|
||||
"其他信息": {
|
||||
"assessment": "不完整",
|
||||
"evidence": {
|
||||
"quote": "None. Declaration of Competing Interest: The authors have no conflicts of interest or funding sources to disclose. Acknowledgments: None.",
|
||||
"location": {
|
||||
"section": "References",
|
||||
"paragraph": 1
|
||||
}
|
||||
},
|
||||
"reasoning": "未提供注册号，但声明了无利益冲突。",
|
||||
"confidence": 0.7
|
||||
}
|
||||
},
|
||||
"processing_log": {
|
||||
"sections_reviewed": [
|
||||
"Abstract",
|
||||
"Introduction",
|
||||
"Methods",
|
||||
"Results",
|
||||
"Discussion",
|
||||
"Tables",
|
||||
"Figures"
|
||||
],
|
||||
"paragraphs_read_per_section": {
|
||||
"Methods": 7,
|
||||
"Results": 5
|
||||
},
|
||||
"middle_sections_attention": true,
|
||||
"total_processing_time_estimate": "15 minutes"
|
||||
},
|
||||
"verification": {
|
||||
"keywords_searched": [
|
||||
"randomization",
|
||||
"blinding",
|
||||
"ITT",
|
||||
"baseline",
|
||||
"dropout"
|
||||
],
|
||||
"reread_count": 2,
|
||||
"found_missed_info": false,
|
||||
"cross_section_conflicts": []
|
||||
},
|
||||
"metadata": {
|
||||
"model_name": "qwen-max",
|
||||
"processing_date": "2023-10-05T14:02:56.003Z",
|
||||
"document_format": "plaintext",
|
||||
"estimated_word_count": 27758
|
||||
}
|
||||
}
|
||||
},
|
||||
"conflict": {
|
||||
"hasConflict": true,
|
||||
"severity": "low",
|
||||
"conflictFields": [
|
||||
"其他信息"
|
||||
],
|
||||
"criticalFieldConflicts": [],
|
||||
"reviewPriority": 5,
|
||||
"details": [
|
||||
{
|
||||
"fieldName": "其他信息",
|
||||
"modelA_assessment": "完整",
|
||||
"modelB_assessment": "不完整",
|
||||
"importance": "normal",
|
||||
"conflictReason": "一个模型认为信息完整，另一个认为不完整"
|
||||
}
|
||||
]
|
||||
}
|
||||
}
|
||||
Reference in New Issue
Block a user